Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
PharmacoEconomics
Published in: PharmacoEconomics 6/2009

01-06-2009 | Original Research Article

Holistic Preferences for 1-Year Health Profiles Describing Fluctuations in Health

The Case of Chronic Obstructive Pulmonary Disease

Authors: Dr Maureen P. M. H. Rutten-van Mölken, Martine Hoogendoorn, Leida M. Lamers

Published in: PharmacoEconomics | Issue 6/2009

Login to get access

Abstract

Background: There are few empirical studies on the valuation of health profiles that describe the short-term fluctuations of chronic diseases.
Objective: This study aimed to value chronic obstructive pulmonary disease (COPD) health profiles, which describe the health of these patients over the course of 1 year from a societal perspective.
Methods: We developed 16 COPD health profiles. Each profile combined a description of the severity of COPD during the stable phase with a description of the exacerbation profile in terms of severity, frequency and duration. These profiles were valued by a representative sample of 239 Dutch adults using the visual analogue scale (VAS) and time trade-off (TTO) methods. Value functions were estimated using random effects regression analysis.
Results: Both VAS and TTO values consistently decreased as severity of the COPD profiles increased. Estimated TTO values ranged from 0.97 for mild COPD without exacerbations to 0.43 for very severe COPD with one non-serious and one serious exacerbation per year. The estimated decrements in TTO values ranged from 0.010 for having one non-serious exacerbation to 0.088 for having one non-serious plus one serious exacerbation per year.
Conclusions: The value function may be an alternative way to model the joint impact of COPD severity and exacerbations on utility values in health economic modelling studies.
Literature
1.
Bleichrodt H, Pinto J. Conceptual foundations for health utility measurement. In: Jones A, editor. The Elgar Companion to Health Economics. Cheltenham: Edward Elgar Publishing Limited, 2006: 347–58
2.
Johannesson M. The ranking properties of healthy-years equivalents and quality-adjusted life-years under certainty and uncertainty. Int J Technol Assess Health Care 1995; 11 (1): 40–8PubMedCrossRef
3.
4.
Mehrez A, Gafni A. Quality-adjusted life years, utility theory, and healthy-years equivalents. Med Decis Making 1989; 9 (2): 142–9PubMedCrossRef
5.
Johannesson M, Pliskin JS, Weinstein MC. Are healthy-years equivalents an improvement over quality-adjusted life years? Med Decis Making 1993; 13 (4): 281–6PubMedCrossRef
6.
Tsuchiya A, Dolan P. The QALY model and individual preferences for health states and health profiles over time: a systematic review of the literature. Med Decis Making 2005; 25 (4): 460–7PubMedCrossRef
7.
Bonsel G, Janssen M, Birnie E. Mild Diseases & Ailments Study (MIDAS). Ziektelastbepaling van 27 vermoedelijk ‘lichte’ ziekten ten behoeve van rationele beperking van het geneesmiddelenpakket: samenvatting. Amsterdam: Amsterdam Medical Centre, Department of Social Medicine, 2003
8.
Brazier J, Dolan P, Karampela K, et al. Does the whole equal the sum of the parts? Patient-assigned utility scores for IBS-related health states and profiles. Health Econ 2006; 15 (6): 543–51PubMedCrossRef
9.
Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23 (6): 932–46PubMedCrossRef
10.
GOLD. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for diagnosis, management, and prevention of COPD. Bethesda (MD): National Institutes of Health, National Heart, Lung and Blood Institute, 2005 [online]. Available from URL: http://​www.​goldcopd.​com [Accessed 2006 Jul 6]
11.
Pauwels R, Calverley P, Buist AS, et al. COPD exacerbations: the importance of a standard definition. Respir Med 2004; 98 (2): 99–107PubMedCrossRef
12.
Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J 2003; 41 Suppl.: 46–53sCrossRef
13.
Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157 (5 Pt 1): 1418–22PubMed
14.
Aaron SD, Vandemheen KL, Clinch JJ, et al. Measurement of short-term changes in dyspnea and disease-specific quality of life following an acute COPD exacerbation. Chest 2002; 121 (3): 688–96PubMedCrossRef
15.
Ruchlin HS, Dasbach EJ. An economic overview of chronic obstructive pulmonary disease. Pharmacoeconomics 2001; 19 (6): 623–42PubMedCrossRef
16.
Rutten-van Mölken M, Lee TA. Economic modeling in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006; 3 (7): 630–4PubMedCrossRef
17.
18.
Rutten-van Mölken MP, Oostenbrink JB, Tashkin DP, et al. Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages? Chest 2006; 130 (4): 1117–28PubMedCrossRef
19.
O’Reilly JF, Williams AE, Rice L. Health status impairment and costs associated with COPD exacerbation managed in hospital. Int J Clin Pract 2007; 61 (7): 1112–20PubMedCrossRef
20.
Decramer M, Rutten-van Molken M, Dekhuijzen PN, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005; 365 (9470): 1552–60PubMedCrossRef
21.
Vincken W, van Noord JA, Greefhorst AP, et al. Improved health outcomes in patients with COPD during 1 year’s treatment with tiotropium. Eur Respir J 2002; 19 (2): 209–16PubMedCrossRef
22.
Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19 (2): 217–24PubMedCrossRef
23.
Streiner D, Norman G. Health measurement scales: a practical guide to their development and use. Oxford: Oxford University Press, 1989
24.
Lamers LM, Stalmeier PF, Krabbe PF, et al. Inconsistencies in TTO and VAS values for EQ-5D health states. Med Decis Making 2006; 26 (2): 173–81PubMedCrossRef
25.
Efron B, Tibshirani R. Cross-validation and other estimates of prediction error. Chapter 17. An introduction to the bootstrap. New York: Chapman & Hall, 1993
26.
Richardson J, Hall J, Salkeld G. The measurement of utility in multiphase health states. Int J Technol Assess Health Care 1996; 12 (1): 151–62PubMedCrossRef
27.
Kuppermann M, Shiboski S, Feeny D, et al. Can preference scores for discrete states be used to derive preference scores for an entire path of events? An application to prenatal diagnosis. Med Decis Making 1997; 17 (1): 42–55PubMedCrossRef
28.
Lipscomb J. Time preference for health in cost-effectiveness analysis. Med Care 1989; 27 (3 Suppl.): S233–53CrossRef
29.
MacKeigan LD, O’Brien BJ, Oh PI. Holistic versus composite preferences for lifetime treatment sequences for type 2 diabetes. Med Decis Making 1999; 19 (2): 113–21PubMedCrossRef
30.
Chapman GB. Preferences for improving and declining sequences of health outcomes. J Behav Dec Making 2000; 13: 203–18CrossRef
31.
Lamers LM, McDonnell J, Stalmeier PF, et al. The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies. Health Econ 2006; 15 (10): 1121–32PubMedCrossRef
32.
Borg S, Ericsson A, Wedzicha JA, et al. A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease. Value Health 2004; 7 (2): 153–67PubMedCrossRef
33.
Oostenbrink JB, Rutten-van Molken MP, Monz BU, et al. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health 2005; 8 (1): 32–46PubMedCrossRef
34.
Hoogendoorn M, Feenstra T, Hoogenveen R, et al. A health policy model for COPD: effects of smoking cessation. Rotterdam: iMTA, Erasmus MC, 2003 Nov
35.
Spencer M, Briggs AH, Grossman RF, et al. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics 2005; 23 (6): 619–37PubMedCrossRef
36.
Sin DD, Golmohammadi K, Jacobs P. Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity. Am J Med 2004; 116 (5): 325–31PubMedCrossRef
37.
Pickard AS, Kohlmann T, Janssen MF, et al. Evaluating equivalency between response systems: application of the Rasch model to a 3-level and 5-level EQ-5D. Med Care 2007; 45 (9): 812–9PubMedCrossRef
38.
Miller G. The magic number seven, plus or minus two: some limits in our capacity for processing information. Psychol Rev 1956; 63 (2): 81–97PubMedCrossRef
39.
Greiner W, Weijnen T, Nieuwenhuizen M, et al. A European EQ-5D VAS valuation set. In: Brooks R, Rabin R, De Charro F, editors. The measurement and valuation of health status using EQ-5D: a European perspective. Dordrecht: Kluwer Academic, 2003: 143–65
40.
Revicki DA, Leidy NK, Brennan-Diemer F, et al. Development and preliminary validation of the multiattribute Rhinitis Symptom Utility Index. Qual Life Res 1998; 7 (8): 693–702PubMedCrossRef
41.
Revicki DA, Leidy NK, Brennan-Diemer F, et al. Integrating patient preferences into health outcomes assessment: the multiattribute Asthma Symptom Utility Index. Chest 1998; 114 (4): 998–1007PubMedCrossRef
Metadata
Title
Holistic Preferences for 1-Year Health Profiles Describing Fluctuations in Health
The Case of Chronic Obstructive Pulmonary Disease
Authors
Dr Maureen P. M. H. Rutten-van Mölken
Martine Hoogendoorn
Leida M. Lamers
Publication date
01-06-2009
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 6/2009
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200927060-00003

Other articles of this Issue 6/2009

PharmacoEconomics 6/2009 Go to the issue

Original Research Article

Determinants of Direct Cost Differences among US Employees with Major Depressive Disorders Using Antidepressants

Leading Article

Cost Effectiveness of Influenza Vaccination in Older Adults

Original Research Article

How to Deal with Cost Differences at Baseline

Original Research Article

Converting the SF-12 into the EQ-5D

Original Research Article

Economic Outcomes Associated with Microvascular Complications of Type 2 Diabetes Mellitus

Leading Article

Pharmacoeconomic Considerations in Treating Actinic Keratosis